Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (SHE:002864) — Market Cap & Net Worth
Market Cap & Net Worth: Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864)
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (SHE:002864) has a market capitalization of $409.65 Million (CN¥2.80 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13415 globally and #4010 in its home market, demonstrating a -3.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's stock price CN¥26.34 by its total outstanding shares 106280960 (106.28 Million). Review total liabilities of Shaanxi Panlong Pharmaceutical Group Lim to assess the company's total debt and financial obligations.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Market Cap History: 2017 to 2026
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's market capitalization history from 2017 to 2026. Data shows growth from $430.88 Million to $409.65 Million (7.67% CAGR).
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.42x
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's market cap is 0.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.98x
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's market cap is 4.98 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $430.88 Million | $376.79 Million | $43.72 Million | 1.14x | 9.86x |
| 2018 | $480.70 Million | $489.45 Million | $64.68 Million | 0.98x | 7.43x |
| 2019 | $415.38 Million | $610.64 Million | $71.78 Million | 0.68x | 5.79x |
| 2020 | $381.73 Million | $670.31 Million | $79.12 Million | 0.57x | 4.82x |
| 2021 | $479.10 Million | $887.48 Million | $93.17 Million | 0.54x | 5.14x |
| 2022 | $596.23 Million | $974.29 Million | $101.16 Million | 0.61x | 5.89x |
| 2023 | $594.09 Million | $980.83 Million | $110.43 Million | 0.61x | 5.38x |
| 2024 | $472.94 Million | $973.86 Million | $120.27 Million | 0.49x | 3.93x |
| 2025 | $479.63 Million | $1.14 Billion | $96.28 Million | 0.42x | 4.98x |
Competitor Companies of 002864 by Market Capitalization
Companies near Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A in the global market cap rankings as of June 19, 2026.
Key companies related to Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Historical Marketcap From 2017 to 2026
Between 2017 and today, Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's market cap moved from $430.88 Million to $ 409.65 Million, with a yearly change of 7.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥409.65 Million | -14.59% |
| 2025 | CN¥479.63 Million | +1.41% |
| 2024 | CN¥472.94 Million | -20.39% |
| 2023 | CN¥594.09 Million | -0.36% |
| 2022 | CN¥596.23 Million | +24.45% |
| 2021 | CN¥479.10 Million | +25.51% |
| 2020 | CN¥381.73 Million | -8.10% |
| 2019 | CN¥415.38 Million | -13.59% |
| 2018 | CN¥480.70 Million | +11.56% |
| 2017 | CN¥430.88 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $409.65 Million USD |
| MoneyControl | $409.65 Million USD |
| MarketWatch | $409.65 Million USD |
| marketcap.company | $409.65 Million USD |
| Reuters | $409.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells Chinese patent medicines in China. It offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chine… Read more